Prospective Cohort Study of Traditional Chinese Medicine for Survival of Patients With Early Breast Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

310 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-11-12

Study Completion Date

2020-10-24

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This 2-year trial is intended to be used to study breast cancer patients through forward-looking generation design through collaboration between Chinese and Western medical teams. The whole study consists of 2 stages, stage I comprises a cross-sectional study-baseline and stage II is a cohort for outcome evaluation and follow-up study across a 3-year period. To provide an empirical basis for combined TCM treatment in the Breast Cancer Research Team and to publish that as a reference for future TCM and Western medicine in integrative cancer treatment.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Clinical Observational Studies:Integrative TCM and Western Medicine for Breast Cancer

NCT07096180

Breast Cancer

RECRUITING

Combination Chemotherapy After Surgery With or Without Chinese Herbal Therapy to Treat Symptoms in Women With Breast Cancer

NCT00028964

Breast Cancer Drug/Agent Toxicity by Tissue/Organ

COMPLETED PHASE1/PHASE2

TCM as an Adjuvant Treatment in Breast Cancer Patients

NCT04843865

Breast Cancer Musculoskeletal Pain

RECRUITING NA

Standardization Research of TCM Syndrome Differentiation and Treatment on Advanced Breast Cancer

NCT02011880

Breast Cancer Bone Metastasis

TEMPORARILY_NOT_AVAILABLE

Aromatherapy in the Treatment of Early Breast Cancer

NCT06435104

Early Breast Cancer

NOT_YET_RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Breast cancer is a major health issue for women worldwide and has increased exponentially in the last decades. Improved earlier detection combined with adjuvant systemic therapy is responsible for much of the reduction in cause-specific mortality from breast cancer. Chemotherapy after surgery can decrease the risk of recurrence and is often used as routine treatment in clinic. Because of the fact that a considerable number of patients seek for traditional Chinese medicine (TCM) during adjuvant chemotherapy, it is thus need to evaluate the correlation between TCM treatment and prognosis. The investigators design a single center, prospective cohort study began in November 2018 in Kaohsiung, Taiwan. A sample of 104 participants diagnosed with early breast cancer was recruited from Breast Cancer Research Team and are followed up every 3 to 6 months till October 2023. Detailed information of participants includes general information, history of cancer, quality of life, side effects of chemotherapy and safety of treatment, body constitution of TCM and meridian energy analysis is taken face-to-face at baseline.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Early-stage Breast Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cohort 1

adjuvant chemotherapy combined with Chinese herbal medicine

Chinese herbal medicine

Intervention Type COMBINATION_PRODUCT

All Chinese herbal products prescribed from TCM physicians in our hospital during patients receiving adjuvant chemotherapy

Cohort 2

adjuvant chemotherapy only

Chinese herbal medicine

Intervention Type COMBINATION_PRODUCT

All Chinese herbal products prescribed from TCM physicians in our hospital during patients receiving adjuvant chemotherapy

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Chinese herbal medicine

All Chinese herbal products prescribed from TCM physicians in our hospital during patients receiving adjuvant chemotherapy

Intervention Type COMBINATION_PRODUCT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Aged \> 20 years old female patients;
* Patients with histologically proven stage 1-3 breast cancer after surgery;
* The duration from the end of radical surgery to the beginning of the trail is less than 1 month;
* ECOG score is 0-2 points;
* Agreed to participate in this study and signed informed consent.

Exclusion Criteria

* Combined with inadequate heart, liver, kidney and hematopoietic function and other serious diseases;
* Pregnant and lactating women;
* Patients with a history of mental illness;
* Patients with distant metastasis and/or expected lifetime less than 3 months;
* Patients undergoing other medicinal herbs outside our hospital.

Minimum Eligible Age

20 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No